85 related articles for article (PubMed ID: 17135223)
41. Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
Braunwald E; Domanski MJ; Fowler SE; Geller NL; Gersh BJ; Hsia J; Pfeffer MA; Rice MM; Rosenberg YD; Rouleau JL;
N Engl J Med; 2004 Nov; 351(20):2058-68. PubMed ID: 15531767
[TBL] [Abstract][Full Text] [Related]
42. National Institute for Clinical Excellence and its value judgments.
Rawlins MD; Culyer AJ
BMJ; 2004 Jul; 329(7459):224-7. PubMed ID: 15271836
[TBL] [Abstract][Full Text] [Related]
43. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
Devlin N; Parkin D
Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Fox KM;
Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
[TBL] [Abstract][Full Text] [Related]
45. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.
Lamy A; Yusuf S; Pogue J; Gafni A;
Circulation; 2003 Feb; 107(7):960-5. PubMed ID: 12600907
[TBL] [Abstract][Full Text] [Related]
46. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease.
Briggs AH; Goeree R; Blackhouse G; O'Brien BJ
Med Decis Making; 2002; 22(4):290-308. PubMed ID: 12150595
[TBL] [Abstract][Full Text] [Related]
47. The estimation of a preference-based measure of health from the SF-36.
Brazier J; Roberts J; Deverill M
J Health Econ; 2002 Mar; 21(2):271-92. PubMed ID: 11939242
[TBL] [Abstract][Full Text] [Related]
48. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Fenwick E; Claxton K; Sculpher M
Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
[TBL] [Abstract][Full Text] [Related]
49. NICE: faster access to modern treatments? Analysis of guidance on health technologies.
Raftery J
BMJ; 2001 Dec; 323(7324):1300-3. PubMed ID: 11731399
[No Abstract] [Full Text] [Related]
50. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model.
Matsumoto K; Morishita R; Moriguchi A; Tomita N; Aoki M; Sakonjo H; Matsumoto K; Nakamura T; Higaki J; Ogihara T
Hypertension; 2001 Feb; 37(2):270-4. PubMed ID: 11230284
[TBL] [Abstract][Full Text] [Related]
51. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
; Yusuf S; Sleight P; Pogue J; Bosch J; Davies R; Dagenais G
N Engl J Med; 2000 Jan; 342(3):145-53. PubMed ID: 10639539
[TBL] [Abstract][Full Text] [Related]
52. An introduction to Markov modelling for economic evaluation.
Briggs A; Sculpher M
Pharmacoeconomics; 1998 Apr; 13(4):397-409. PubMed ID: 10178664
[TBL] [Abstract][Full Text] [Related]
53. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
Brown NJ; Agirbasli MA; Williams GH; Litchfield WR; Vaughan DE
Hypertension; 1998 Dec; 32(6):965-71. PubMed ID: 9856958
[TBL] [Abstract][Full Text] [Related]
54. Deriving a preference-based single index from the UK SF-36 Health Survey.
Brazier J; Usherwood T; Harper R; Thomas K
J Clin Epidemiol; 1998 Nov; 51(11):1115-28. PubMed ID: 9817129
[TBL] [Abstract][Full Text] [Related]
55. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.
Ware JE; Gandek B
J Clin Epidemiol; 1998 Nov; 51(11):903-12. PubMed ID: 9817107
[TBL] [Abstract][Full Text] [Related]
56. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.
Hornig B; Kohler C; Drexler H
Circulation; 1997 Mar; 95(5):1115-8. PubMed ID: 9054837
[TBL] [Abstract][Full Text] [Related]
57. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.
Rutherford JD; Pfeffer MA; Moyé LA; Davis BR; Flaker GC; Kowey PR; Lamas GA; Miller HS; Packer M; Rouleau JL
Circulation; 1994 Oct; 90(4):1731-8. PubMed ID: 7923656
[TBL] [Abstract][Full Text] [Related]
58. Costs, effects and C/E-ratios alongside a clinical trial.
van Hout BA; Al MJ; Gordon GS; Rutten FF
Health Econ; 1994; 3(5):309-19. PubMed ID: 7827647
[TBL] [Abstract][Full Text] [Related]
59. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.
Yusuf S; Pepine CJ; Garces C; Pouleur H; Salem D; Kostis J; Benedict C; Rousseau M; Bourassa M; Pitt B
Lancet; 1992 Nov; 340(8829):1173-8. PubMed ID: 1359258
[TBL] [Abstract][Full Text] [Related]
60. Letter: Grading of angina pectoris.
Campeau L
Circulation; 1976 Sep; 54(3):522-3. PubMed ID: 947585
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
